Publications

Presentations

Event
American Association for Cancer Research (AACR) Annual Meeting San Diego, CA \| April 2024 Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathway CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization
ESMO Immuno-Oncology (IO) Annual Congress Geneva, Switzerland \| December 2023 Discovery of a Novel, Dual CD73 & PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer [Poster] [Abstract] Discovery of CBO421, a First-in-Class Drug Fc-Conjugate (DFC), Targeting CD73 in Cancer [Poster] [Abstract]
Society for Immunotherapy of Cancer (SITC) San Diego, CA \| November 2023 Discovery of CBO421, a First-in-Class Drug Fc-conjugate (DFC), Targeting CD73 in Cancer [Poster] [Abstract]
IDWeek Boston, MA \| October 2023 Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), is Driven by the Small Molecule Neuraminidase Inhibitor (NAI) In Vivo Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), Against Seasonal Subtypes of Influenza in Prophylaxis in Immune Competent Mice, and in a Severe Immunodeficient (SCID) Mouse Model Single Ascending Dose Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza [2514]
Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit Boston, MA \| June 2023 Cidara Drug-Fc-Conjugates (DFCs): A New Approach to Treatment of Cancer
International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Seattle, WA \| May 2023 CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates Potent, Universal Activity Against Influenza A and B CD388 Demonstrates a High Barrier to Resistance and Retains Potent Activity Against NAI Influenza A and B
ESMO Targeted Anticancer Therapies Paris, France \| March 2023 Discovery of CBO-212, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
ESWI Keynote Lecture \| December 2020 Beyond Vaccines and mAbs: Progress Towards Universal Influenza Protection with Cloudbreak^® Influenza Antiviral Conjugates (AVCs)
ESWI VIRTUAL \| December 2020 In Vitro Potency and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Highly Pathogenic Avian Influenza (HPAI) [139] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, by Multiple Dosing Routes Against Influenza A (H1N1), and Activity Against Oseltamivir-Resistant Isolates in Lethal Mouse Models [159] Characterization of In Vitro Activity and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine Strains [269]
IDWeek VIRTUAL \| October 2020 Efficacy of CD377, a Novel Antiviral Fc-conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models [159] CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models [162] Evaluation of CD377, a Novel Antiviral Fc-Conjugate (AVC), In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models [1276] New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single [1283]
IDWeek Washington, D.C. \| October 2019 Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria) [689]